Voyager Therapeutics has exercised commercial options for the use of Regenxbio’s NAV ® vectors to develop and commercialize gene therapies for specific neurological diseases, the companies said today.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback